研究者業績
基本情報
研究キーワード
5研究分野
1経歴
12-
2022年7月 - 現在
-
2022年7月
-
2015年4月 - 2022年6月
-
2013年7月 - 2022年6月
学歴
2-
2012年4月 - 2013年3月
-
1994年4月 - 2000年3月
委員歴
4-
2019年2月 - 現在
-
2018年4月 - 現在
-
2014年1月 - 2017年12月
受賞
8-
2019年2月
-
2012年10月
論文
100-
Infectious diseases and therapy 2025年4月10日 査読有りLower respiratory tract infections caused by SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) cause a significant disease burden globally, despite the availability of effective vaccines. Certain populations, such as older adults (≥ 60 years) and individuals of all ages with particular comorbidities, are at increased risk for severe outcomes, including hospitalization and death. National administration schedules for available vaccines against respiratory viruses are not unified, and not all current guidelines are clear and directive, concerning the optimal timing of vaccination. Herein, we formulate an evidence-based position regarding the optimal timing of COVID-19, influenza, and RSV vaccination for older adults and individuals with chronic comorbidities, based on a synthesis of the literature and current guidelines. Vaccination impact and timing were found to be influenced by vaccinee risk factors, including age and comorbidities, and waning vaccine effectiveness and seasonal pathogen burden. Because COVID-19, influenza, and RSV display unique seasonal patterns within and between regions, local epidemiological surveillance of each virus is crucial for determining optimal vaccination timing and guidelines. To maximize the benefits of these respiratory virus vaccines, the timing of peak vaccine effectiveness and period of greatest risk for severe outcomes should be aligned. Thus, COVID-19, influenza, and other recommended vaccines given ahead of the start of the respiratory virus season (or other regionally appropriate time) and co-administered at a single, routine visit represent the optimal approach to protecting at-risk populations. More data will be required to establish the clinical benefit of additional RSV vaccine doses and whether these may be integrated within a seasonal schedule. Coordinated policy decisions that align with strain selection for new and annually reformulated vaccines would enable the timely raising of public health awareness, ultimately leading to enhanced vaccine uptake. Implementation strategies will require engagement of healthcare providers and strong, evidence-based public health recommendations for integrated vaccine schedules.
-
Infection Control & Hospital Epidemiology 2025年4月3日
-
Sexually Transmitted Diseases 2025年2月25日 査読有り最終著者責任著者
-
Infection Control & Hospital Epidemiology 2025年2月14日 査読有り最終著者責任著者
-
Asia-Pacific journal of public health 10105395241305929-10105395241305929 2024年12月17日 査読有りFew longitudinal studies have examined the impact of the COVID-19 pandemic on personal behaviors. This study investigated changes in four social behaviors among the Japanese public during and after the COVID-19 pandemic, using four-wave longitudinal data (2020-2023) from the Japan COVID-19 and Society Internet Survey (JACSIS). In total, 8622 respondents continuously participated in the surveys. In JACSIS 2023, the percentage of individuals who always refrained from specific actions decreased compared with 2020: traveling (71.0%-30.9%), non-essential and non-urgent outings (60.6%-24.5%), crowded spaces (62.6%-28.0%), and eating out (49.5%-21.6%). Mixed-effects logistic regression analysis indicated that essential health care workers displayed more cautious behavior than other workers, and respondents were less likely to refrain from these actions in JACSIS 2023 compared with 2020. Understanding behavioral changes is crucial to evaluating the efficacy of COVID-19 prevention measures and improving future pandemic response strategies.
MISC
106-
Intensivist 15(4) 607-615 2023年10月<文献概要>ICUに入室する患者には,背景に免疫不全の病態を有する患者が数多く存在している。免疫不全患者が感染症に罹患した際の予後は一般的に悪い。また,昨今さまざまな免疫抑制剤や抗腫瘍薬が使用可能となり,各薬物投与後に生じる,いくつかの特徴的な感染症が認知されている。一般に免疫不全患者の感染症では,想定される起炎菌,使用すべき抗微生物薬も一般の感染症と異なることがあり,この分野の感染症診療の包括的な教育が必要である。
書籍等出版物
5共同研究・競争的資金等の研究課題
3-
日本学術振興会 科学研究費助成事業 2023年4月 - 2026年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(C) 2019年4月 - 2022年3月
-
日本学術振興会 科学研究費助成事業 基盤研究(C) 2016年4月 - 2020年3月